drugset / Trial / NCT05554068
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.
Timeline
- Start
- 2023-03-07
- Primary completion
- 2025-03-07
- Completion
- 2026-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E | Vaccine | — | — |